Viemed reported record 3Q26 revenue of $80.7M, up 12.2% y/y, while adjusted EBITDA increased to $17.1M and net income rose 32% to $4.6M. Profitability improved meaningfully sequentially, with adjusted EBITDA margin expanding approximately 350 bps to 21.1%, while continued growth in sleep therapy and resupply helped diversify the revenue base. PAP therapy patients increased 37.5% y/y to 43,861 and sleep resupply patients increased 22.1% to 40,918, while ventilator rental revenue grew 7.4% to $37.5M. Management narrowed FY26 guidance to $316M–$320M of revenue and $64M–$66M of adjusted EBITDA while lowering net CapEx guidance to 8%–9% of revenue, supporting continued sequential growth and improving cash-flow potential.